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BACKGROUND: Cervical cancer is one of the most prevalent cancers in women. Even with similar clinicopathologic features, radiotherapy outcomes 
are still vary among patients. This research was conducted 
to measure radiotherapy responses on cervical cancer 
patients by using Survivin, Telomerase and Cytochrome C.
METHODS: Subjects who matched the criteria were 
selected and requested to fill questionnaires. Subjects were 
then evaluated with magnetic resonance imaging (MRI) 
pre- and post-3D conformal radiotherapy. Histopathological 
study was conducted using resected tumors to determine the 
differentiation type. Enzyme-linked Immunosorbent Assays 
for detection of Survivin, Telomerase and Cytochrome C 
was performed using the resected tumors as well.
RESULTS: There were 76 patients in this study. Mean of 
age was 50 and diameter of tumor size was 5.35 cm. Mean 
levels of Survivin, Telomerase and Cytochrome C were 
632.82 pg/mL, 5.59 pg/mL and 204.75 ng/mL, respectively. 
There were significant correlations between radiotherapy 
response and Survivin (p=0.041) or Telomerase (p=0.022). 
Subjects with lower Survivin level (<932 pg/mL) had 
higher 1-year survival rate (63%) than subjects with higher 
Survivin level (50%). Similar results were obtained for 
subjects with lower Telomerase level (<5.75 pg/mL), who 
had higher 1-year survival rate (60%) than subjects with 
higher Telomerase level (43%).
CONCLUSION: Since radiotherapy response is 
significantly correlated with Survivin and Telomerase 
levels and subjects with lower Survivin or Telomerase 
level have higher 1-year survival rate, it can be suggested 
that Survivin and Telomerase could be potential predictors 
of radiotherapeutic response for subjects with stage IIIB 
cervical squamous cell carcinoma.
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Abstract
Introduction
Cervical cancer is one of the most common cancers in 
women. Human Papilloma Virus (HPV) is closely related 
to the occurrence of cervical cancer.(1-4) The incidence of 
cervical cancer in Indonesia is 100 among 100.000 women. 
The mortality rate of patients with cervical cancer is still high 
(90%), since the patients seek for help in the advanced stage 
of disease.(5) Nearly 70% of patients with cervical cancer in 
Dr. Cipto Mangunkusumo Hospital Jakarta were in the stage 
of IIB to IVB. Therefore, the outcome of treatments were 
still far from satisfaction.(6) Radiotherapy and palliative 
chemotherapy are the treatments of choice for cervical 
cancer stage IIB to IVB.(7-9) However, there are failures in 
radiotherapy, 10% at stage IIB, 42% at stage III and 74% at 
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stage IVA.(10) Success in cervical cancer therapy depends 
on clinicopathologic features, such as the cancer stage, 
tumor size, histopathological type, differentiation level and 
lymphocyte reaction.(5) However, radiotherapy outcomes 
in similar clinicopathologic features are not always alike. 
 Various tumor markers were studied to determine 
prognostic factor, such as serum associated antigen, 
angiogenic factor and apoptotic factor. Angiogenic factor 
was reported to have a role in early stadium, meanwhile 
apoptotic factor in both early and late stadiums.(11,12) 
Therefore, apoptotic factor such as Cytochrome C is 
important to be investigated. Cytochrome C, which is 
produced by mitochondria, comprises 104 amino acids and 
plays an important role in cellular development or death.
(13)  Cytochrome C plays a role in the intrinsic pathway 
type 2 via the mitochondrial electron transport system. The 
role of Cytochrome C has been reported in various humans 
cancers, including thyroid (14), lung (15), colon (16), 
prostate (17), breast (18,19), ameloblastoma (20), ovarian 
(21) and cervical cancers (22,23).
 Despite Cytochrome C, Survivin also plays an 
important role in the apoptotic pathway. Survivin is a 
member of the inhibitor of apoptosis (IAP) gene family, 
comprises 142 amino acids. Survivin has the capability to 
control cell proliferation and apoptosis.(24,25) Level of 
Survivin is very low in healthy tissue, but it is increasing 
in tumor tissue.(24,26) Survivin overexpression is currently 
used as prognostic factor in the brain (27), breast (28), rectal 
(29) and bladder (30) cancers. In addition, level of Survivin 
has been used as a predictor for treatment outcome. Based 
on cumulative incidences in five years, the cancer recurrence 
is greater in patients with higher level of Survivin.(29)
 Telomerase is a ribonucleoprotein that adds a 
species-dependent telomere repeat sequence to the 3' 
end of telomeres. By preventing DNA from shortening 
with each cell cycle, Telomerase is able to inhibit cellular 
senescence and apoptosis.(31) Telomerase activity was 
detected in 96.5% of cervical tumor samples and in 68.7% 
of premalignant cervical scrapings but it was not detected 
in control hysterectomy samples nor in cervical scrapings 
of normal healthy control. Therefore the absence of 
Telomerase activity in cervical scrapes of healthy women 
indicated the potential of Telomerase as a screening marker 
for early diagnosis of cervical cancer.(32) Since Cytochrome 
C, Survivin and Telomerase are important biomarkers for 
cervical cancers, therefore the present study was conducted 
to investigate the correlation of these biomarkers with the 
outcome of radiotherapy in the advanced stage of cervical 
cancer. 
Methods
Subject Recruitment and Selection
A  prospective  study  with  nested  case-control  method 
was conducted to see the role of Survivin, Telomerase and 
Cytochrome C as markers of cervical cancer radiotherapy 
outcomes in addition to clinicopathologic features. The 
study  was  conducted  in  Dr.  Cipto  Mangunkusumo 
National Central General Hospital, Jakarta, from January 
2016 to May 2017. Subjects were recruited and selected 
based on the inclusion criteria of having untreated 
cervical  cancer  with  the  extension  into  the  pelvic 
sidewall, hydronephrosis or non-functioning kidney 
with histopathologic type of squamous  cell  carcinoma 
(stage  IIIB  according  to Fédération Internationale de 
Gynécologie et d'Obstétrique (FIGO) staging of cervical 
cancer). Meanwhile the exclusion criteria were subjects 
diagnosed with Human Immunodeficiency Virus (HIV), 
severe  systemic  diseases,  heart  disease,  sclerosis  and 
wound healing. Prior to recruitment and selection, all 
subjects had agreed to participate in the study and signed 
the informed consent. The study protocol was approved 
by the Research Ethics Committee, Faculty of Medicine, 
Universitas Indonesia (Ethical clearance No. 446/UN2.F1/
ETIK/2015).
Radiotherapy
Subjects who matched the criteria were evaluated with 
magnetic resonance imaging (MRI) before starting the 
radiotherapy. Radiotherapy was done using 3D conformal 
radiotherapy. The total dosage were 70 Gy, consist of 
external radiation for whole pelvis as primary therapy at 
a dose of 45-50 Gy divided into 1.8-2 Gy each fraction, 
5 fraction per week (total 25-28 fractions), followed by 
Ir192 afterloading high-dose-rate (3x7 Gy) intracaviter 
brachytherapy. After 2-3 months, the therapy response was 
re-evaluated with MRI. 
 Radiotherapy responses were divided into good and 
poor response. Good response subjects were those who had 
complete response (no lesion, no new lesion, and no related 
symptom) or partial response (≥30% reduction of lesion 
size, no new lesion, no progressive disease). Poor response 
group was further divided into progressive response or no 
response. The definition of progressive response was >20% 
increase of the lesion size, growth of a new lesion, or the 
deterioration of the disease. No response subjects were 
those who could not be qualified as complete, partial, or 
progressive response. 
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Histopathology
Sections  from  the  resected  tumors  were  prepared  and 
stained   with   hematoxylin   and   eosin.   The   sections 
were  then  analyzed  by  a  pathologist  to  determine 
the  differentiation type (well differentiated, moderately 
differentiated, poorly differentiated, and undifferentiated), 
based on The World Health Organization (WHO) 
classification. 
Enzyme-linked Immunosorbent Assay (ELISA) for 
Survivin, Telomerase and Cytochrome C
ELISA for Survivin, Telomerase and Cytchrome C were 
performed using Human Surv (Survivin) ELISA Kit (Catalog 
No.: E-EL-H1584, Elabscience, Houston, USA), Human 
TE (Telomerase) ELISA Kit (Catalog No.: E-EL-H0164, 
Elabscience) and Human Cyt-C (Cytochrome C) ELISA Kit 
(Catalog No.: E-EL-H0056, Elabscience). Basically, each 
micro ELISA plate provided was pre-coated with an antibody 
specific to human Survivin, Telomerase or Cytochrome C. 
Standards or the resected tumor samples were added to the 
micro ELISA plate wells and combined with the specific 
antibodies. Then an Avidin-Horseradish Peroxidase (HRP)-
conjugated detection antibody specific for human Survivin, 
Telomerase or Cytochrome C was added to each micro plate 
well and incubated. After washing, the substrate solution 
was added to each well. Only wells containing human 
Survivin, Telomerase or Cytochrome C appeared in blue 
color. The enzyme-substrate reaction was terminated by the 
addition of stop solution and the color turned yellow. The 
optical density (OD) was measured spectrophotometrically 
at a wavelength of 450 nm±2 nm. The OD value was 
proportional to the concentration of  human Survivin, 
Telomerase or Cytochrome C. Concentration of human 
Survivin, Telomerase or Cytochrome C in the samples 
was calculated by comparing the OD of the samples to the 
standard curve.
Statistical Analysis
Collected data were analyzed using SPSS for Macintosh ver. 
20 (IBM Corp., Armonk, NY, USA). Bivariate analysis to 
assess relation of Survivin, Telomerase, and Cytochrome C 
activity on radiotherapy response was done by determining 
the value of Survivin, Telomerase, and Cytochrome 
C activity limit considered significant using Receiver 
Operating Characteristic (ROC). Furthermore, bivariate 
analysis was done to find the correlation between variables 
using chi-square method. If the requirement of chi-square 
test was not fulfilled, Fisher test would be done to evaluate 
the correlation between variables.
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<20 years old 33 (43.4%)
≥20 years old 43 (56.6%)
3 (0-8)
5.35 (1.9 – 15.0)
well and moderately 19 (25.0%)
poor and undifferentiated 57 (75.0%)
positive 49 (61.8%)
negative 27 (38.2%)
Radiotherapy response
Characteristics
Mean of age (years old)
First sexual intercourse
Median of parity
Diameter of tumor (cm)
Differentiation type*
Table 1. Subjects characteristics (n=76).
*Based on WHO
Results
A total of 76 subjects who met the criteria was further 
analyzed. Subject characteristics are shown in Table 1. 
Bivariate analyses of relation between subject characteristics 
and radiotherapy response were performed. There was no 
significant correlation between radiotherapy response and 
age (p=0.07), parity (p=0.22), first sexual intercourse age 
(p=0.43), diameter of tumor (p=0.32) and differentiation 
type (p=0.08). 
 Mean levels of Survivin, Telomerase and Cytochrome 
C were 632.82 pg/mL, 5.59 pg/mL and 204.75 ng/mL, 
respectively. Survivin, Telomerase and Cytochrome C levels 
were categorized using ROC curve analysis. Cut off limit 
of Survivin was set to 932 pg/mL, considering likelihood 
ratio (LR)+ value of 2.54, sensitivity 37.90%, specificity 
85.10%, and accuracy of 57.90% (Figure 1A). Cutoff limit 
of Telomerase was set to 5.75 pg/mL, considering LR+ 
value of 2.26, sensitivity 46.80%, specificity 79.30%, and 
accuracy of 63.05% (Figure 1B). Meanwhile, cut off limit of 
Cytochrome C was set to 122.92 ng/mL, considering LR+ 
value of 1.09, sensitivity 78.70%, specificity 27.60%, and 
accuracy of 53.15% (Figure 1C).
 Based on chi-square analysis, there were significant 
correlation between radiotherapy response and Survivin 
(p=0.041) or Telomerase (p=0.022). Relative risk of this 
study was 1.833 (1.067-3.150, CI 95%) for Survivin (Table 
2) and 2.236 (1.038-4.820, CI 95%) for Telomerase (Table 
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Figure 1. ROC curve of Survivin, Telomerase and 
Cytochrome C. A: ROC curve of Survivin, B: ROC curve of 
Telomerase, C: ROC curve of Cytochrome C.
Poor Good
≥932 11 (57.9%) 8 (42.1%) 19 (25.0%)
<932 18 (31.6%) 39 (68.4%) 57 (75.0%)
Total 29 (38.2%) 47 (61.8%) 76 (100.0%)
0.041* 1.833 
(1.067–3.150, CI 95%)
Survivin Level 
(pg/mL)
Response
Total p -value Relative Risk
Table 2. Bivariate analysis between Survivin level and radiotherapy response.
*Tested with chi-square.
3). However, there was no significant correlation between 
radiotherapy response and Cytochrome C (p=0.530).
 Kaplan-Meier study was also done in this study to 
compare the subject survival rate of stage IIIB cervical 
squamous cell carcinoma with Survivin (Figure 2) and 
Telomerase (Figure 3). Subjects with lower Survivin level 
(<932 pg/mL) had higher 1-year survival rate (63%) than 
subjects with higher Survivin level (50%). Similar results 
were obtained for subjects with lower Telomerase level 
(<5.75 pg/mL), who had higher 1-year survival rate (60%) 
than subjects with higher Telomerase level (43%). 
From 2016 to 2017, most of patients with stage IIIB cervical 
squamous cell carcinoma in Dr. Cipto Mangunkusumo 
National Central General Hospital were 50 years old and 
had 3 children. This data is similar to a previously reported 
study which showed that the risk of having cervical cancer 
was higher in patients age of 50 years or more with odd 
ratio of 2.53.(7) However, our results showed no significant 
correlation between age, first sexual intercourse age, and 
Discussion
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Poor Good
≥5.75 23 (47.9%) 25 (52.1%) 48 (63.2%)
<5.75 6 (21.4%) 22 (78.6%) 28 (36.8%)
Total 29 (38.2%) 47 (61.8%) 76 (100.0%)
0.022* 2.236 
(1.038–4.820, CI 95%)
Telomerase Level 
(pg/mL)
Response
Total p -value Relative Risk
Table 3. Bivariate analysis between Telomerase level and radiotherapy response.
*Tested with chi-square.
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Figure 2. Kaplan  Meier  graph  of  1-year-survival  subjects 
with high and low Survivin level. Blue line: subjects with 
lower level of Survivin;  Green line: subjects with higher level of 
Survivin.
Figure 3. Kaplan  Meier  graph of  1-year-survival  subjects 
with high and low Telomerase level. Blue line: subjects with 
higher level of Telomerase;  Green line: Subjects with lower level 
of Telomerase.
parity with radiotherapy outcome in stage IIIB cervical 
squamous cell carcinoma patients. Previous study also 
reported no significant correlation in patient age, overall 
survival, and relapse free survival.(8)
 Our results showed that subjects with ≥932 pg/
mL Survivin had significant lower 1-year-survival after 
radiotherapy. This is in accordance with another report that 
Survivin overexpression is correlated significantly with 
lower complete remission.(33) Overexpression of Survivin 
has a poor prognosis and high resistance to therapy. Survivin 
inhibits both extrinsic and intrinsic apoptotic pathways.(24) 
Survivin mutants (Thr34-Ala, Ser81Ala, Cys84Ala,) have 
more potential to inhibit the growth of hepatocellular cancer 
compared to the use of either one mutant alone.(34-37)
 Subjects with high level of Telomerase (≥5.75 pg/mL) 
had significant poor response to radiotherapy, suggesting 
that low level of Telomerase had a better prognosis of 
radiotherapy responses. Similar studies showed that low 
level of Telomerase had a better radiotherapy response. 
Another study reported that Telomerase had roles in tumor 
development and induction of chromosomal instability, 
therefore Telomerase activity can serve as a tumor marker.
(38) In the contrary, the absence of proliferation was 
observed in human cells due to lack of Telomerase. Lack 
of Telomerase will limit tumor cell growth that duplicate 
continuously. Thus Telomerase inhibitor is a promising 
factor in eliminating cancer cells.(39)
 Level of Cytochrome C was not correlated significantly 
with the radiotherapy response and 1-year-survival. Low 
level of Cytochrome C in the cytoplasm are assumed due 
to Cytochrome C was reserved in the mitochondria and not 
been released into the cytoplasm. Level of Cytochrome C 
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will be increased in the cytoplasm if there is a cell damage.
(40) Therefore, level of Cytochrome C should be further 
investigated at a correct time point after radiotherapy.
 A scoring model to predict the radiotherapy response 
was calculated based on Z value of multivariate analysis. 
The coefficient of variable beta scoring that correlated 
(p-value<0.5) with the radiotherapy response was 
coefficient of Survivin: (2.65/3.89)x10=6.8 and coefficient 
of Telomerase: (3.89/3.89)x10=10. So the scoring model 
is 6.8S+10T with S for Survivin and T for Telomerase. 
The scoring model cut-off point is ≥13.4 to determine the 
prediction of negative response. This cut-off point has 
values of LR+ 2.08, specificity 85.1%, sensitivity 31.0% and 
accuracy 58.5%. From the value of LR+ can be calculated 
the probability value after test is 67.5%. The probability 
of patients with a predictor score of ≥13.4 had a negative 
response increased to 67.5%. The predictor score of ≥13.4 
is a sufficient diagnostic test to predict a negative response 
in stage IIIB cervical cancer patients.
Conclusion
Radiotherapy response is significantly correlated with 
Survivin and Telomerase levels of subjects with stage 
IIIB cervical squamous cell carcinoma. In addition, 
the subjects  with  lower  Survivin  or  Telomerase 
level,  have higher 1-year survival rate.  Taken together, 
Survivin and Telomerase  could  be  potential  predictors 
of  radiotherapeutic response for subjects with stage IIIB 
cervical squamous cell carcinoma.
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